How biocompatible haemodialysers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration : a cross-over study by Vanommeslaeghe, Floris et al.
O R I G I N A L A R T I C L E
How biocompatible haemodialysers can conquer the
need for systemic anticoagulation even in post-dilution
haemodiafiltration: a cross-over study
Floris Vanommeslaeghe1, Iván Josipovic2, Matthieu Boone2,
Arjan van der Tol1, Annemie Dhondt1, Wim Van Biesen1 and Sunny Eloot 1
1Department of Nephrology, Ghent University Hospital, Ghent, Belgium and 2Centre for X-ray Tomography,
Physics and Astronomy, Ghent University, Ghent, Belgium
Correspondence to: Sunny Eloot; E-mail: sunny.eloot@ugent.be
ABSTRACT
Background. While systemic anticoagulation is most widely used in haemodialysis (HD), contraindications to its use might
occur in particular settings. The Solacea
TM
haemodialyser with an asymmetric triacetate membrane claims improved
biocompatibility and has already shown promising results when used in combination with only half dose of
anticoagulation. To quantify the performance of the Solacea
TM
when further decreasing anticoagulation to zero, fibre
blocking was assessed by micro-computed tomography (micro-CT).
Methods. Ten maintenance HD patients underwent six dialysis sessions at midweek using a Solacea
TM
19H dialyser,
consecutively in pre-dilution haemodiafiltration (pre-HDF), HD and post-dilution HDF (post-HDF). After the first three
sessions with only a quarter of their regular anticoagulation dose (one-quarter), the last three sessions were performed
without anticoagulation (zero). Dialyser fibre blocking was quantified in the dialyser outlet potting using a 3D micro-CT
scanning technique post-dialysis.
Results. Even in case of reduced (one-quarter) anticoagulation, the relative number of open fibres post-dialysis was almost
optimal, i.e. 0.96 (0.87–0.99) with pre-HDF, 0.99 (0.97–0.99) with HD and 0.97 (0.92–0.99) with post-HDF. Fibre patency was
mildly decreased for pre-HDF and HD when anticoagulation was decreased from one-quarter to zero, i.e. to 0.76 (0.61–0.85)
with pre-HDF (P¼0.004) and to 0.80 (0.77–0.89) with HD (P¼0.013). Comparing the results for zero anticoagulation, post-HDF
[i.e. 0.94 (0.82–0.97)] performed as well as HD and pre-HDF.
Conclusions. The Solacea
TM
dialyser provides promising results for use in conditions where systemic anticoagulation is
contraindicated. Post-HDF, although inducing haemoconcentration in the dialyser, is equally effective for fibre patency in
case of zero anticoagulation as pre-HDF and HD when using Solacea
TM
.
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INTRODUCTION
During haemodialysis (HD), coagulation is activated when blood
comes into contact with the extracorporeal circuit (ECC). While
systemic anticoagulation with heparin is most widely used,
contraindications to its use might occur in specific settings. But,
heparin-free HD, such as regional citrate anticoagulation or pe-
riodic saline flushes to rinse the ECC, are time-consuming tech-
niques and might have undesired side effects such as
alkalization or fluid overload.
Literature seems to provide conflicting results on the impact
of dilution on anticoagulation. It was already suggested in the
1990s that pre-dilution haemodiafiltration (pre-HDF) could be
an alternative to saline flushes as it also results in continuous
rinsing of the circuit but without fluid overload [1]. Accordingly,
pre-HDF is increasingly being used in conditions where anticoa-
gulation is contraindicated [2]. However, some data indicate
that saline flushes and convective techniques may promote
rather than antagonize coagulation [3, 4].
Membranes used for online HDF treatment must have high per-
meability while ideally avoiding albumin leakage. Synthetic mem-
branes such as polysulfone and polyethersulfone generally satisfy
these requirements, but might also be associated with hypersensi-
tivity reactions, ascribed to additives like polyvinylpyrrolidone to
enhance the membrane’s hydrophilicity. Evidence suggests that
the asymmetric triacetate (ATA
TM
) membrane, manufactured with-
out hydrophilization agents, has a lower risk of hypersensitivity,
and induces less decrease in platelets (Plts) as indication of an ex-
cellent biocompatibility [5]. The Solacea
TM
haemodialyser incorpo-
rates such an asymmetric triacetate membrane, and is reported to
have good biocompatibility, and high permeability and filtration
performance. In a head to head comparison with half-dose of anti-
coagulation, virtually no signs of fibre blocking could be observed
when using the Solacea
TM
dialyser, while clotting was much more
present in a polysulfone dialyser [6].
The aim of this prospective cross-over study was to objectively
quantify the performance of the Solacea
TM
dialyser when reducing
anticoagulation to zero. To investigate the impact of haemodilu-
tion under these circumstances of pro-coagulation, tests were ex-
ecuted in three different dialysis modes, i.e. HD, pre-HDF and
post-dilution HDF (post-HDF). Fibre blocking was objectively
assessed by 3D micro-computed tomography (micro-CT).
MATERIALS AND METHODS
Patients
This single-centre cross-over study included 10 consecutive sta-
ble chronic HD patients (mean 6 SD age 58.6 6 17.0 years; nine
male). Patients were eligible when they had experienced stable
dialysis sessions during the last 4 weeks, and had no known co-
agulation disorder, active inflammation or malignancy. Power
analysis was based on data from a previously performed cross-
over study in patients dialysed with two different types of dia-
lyser [6]. Using the relative number of patent fibres as primary
outcome, power was 69% (a¼ 0.05) including only six patients.
Double-needle vascular access was achieved through a na-
tive arteriovenous fistula (n¼ 8) or a well-functioning double-lu-
men tunnelled central venous catheter, either HaemostarVR
14.5 F (n¼ 1) (Bard, Salt Lake City, UT, USA) or PalindromeTM 14.5F
(n¼ 1) (Medtronic, Minneapolis, MN, USA). Regular treatment of
these patients was post-HDF with FX800 dialyser (n¼ 9)
(Fresenius Medical Care, Bad Homburg, Germany) and pre-HDF
with Evodial 1.3 (n¼ 1) (Baxter, Deerfield, IL, USA).
The protocol adhered to the Declaration of Helsinki, and was
approved by the institutional research committee (Ethical
Committee, Ghent University Hospital, EC 2017/1459—
B670201734230, March 2018), and was registered as part of a
larger study in www.ClinicalTrials.gov (NCT03820401). Written
informed consent was obtained from all included patients.
Dialysis and anticoagulation
In the study protocol, each patient was dialysed for 240 min in
six different regimens, using three different dialysis modes and
two different anticoagulation schemes. All study sessions were
performed at midweek with the ATA
TM
SolaceaTM 19H dialyser
(Nipro, Osaka, Japan). The three performed dialysis modes were
HD, and pre- and post-HDF. Patients received their regular
brand of low molecular weight heparin (LMWH) anticoagulation
(Tinzaparin, Leo Pharma, Belgium) at the beginning of the dialy-
sis session at only a quarter of their regular dose (one-quarter
anticoagulation) or dialysis was performed without any anticoa-
gulation (zero anticoagulation). For safety reasons, we first per-
formed the three sessions at one-quarter anticoagulation in the
order of pre-HDF, HD and post-HDF, before the three sessions
with zero anticoagulation. According to protocol, it was planned
that in case a test session had to be terminated prematurely,
the following test session would not be executed in that patient,
and a complete blocking would be registered for that patient for
that session.
All test sessions were performed on a 5008 dialysis machine
(Fresenius Medical Care, Bad Homburg, Germany) with blood
flow at 300 mL/min and dialysate flow at 500 mL/min. In pre-
and post-HDF, substitution flow was set at, respectively, 50 and
25% of blood flow (i.e. 150 and 75 mL/min). Ultrafiltration rates
were set according to the patient’s inter-dialytic weight gain
and clinical status.
Each experimental session was preceded by two wash-in
sessions with the same type of dialyser to be used in the experi-
mental dialysis at midweek, but always with full regular antico-
agulation dose. Each patient served as his/her own control.
Micro-CT scanning and coagulation quantification
To quantify fibre blocking after 4-h dialysis, dialysers were
scanned with a reference non-invasive micro-CT scanning tech-
nique [7]. In brief, at the end of the dialysis session, a standard
rinsing procedure of the haemodialyser was performed with ex-
act 300 mL rinsing solution. Next, the haemodialyser was dried
for 4 h using continuous mild positive pressure ventilation,
simultaneously in blood and dialysate compartment. Dialyser
fibre blocking was visualised in the dialyser outlet potting
using a 3D CT scanning technique on micrometre resolution, as
previously described [7].
For this study, three different thresholds were used to define
the surface area of an open fibre: i.e. 50, 70 and 90% of the cross-
section of a non-used fibre. Comparing the number of non-
blocked fibres in the tested dialyser with the total number of
fibres as measured in three non-used dialyser samples, pro-
vided an objective estimate of the percentage of fibre blocking.
Statistical analysis
Statistical analyses were performed using SPSS version 26 (SPSS
Inc., Chicago, IL, USA). Continuous variables were
summarised as mean 6 SD , and median value with interquar-
tile range (IQR). Normality was checked with Shapiro–Wilk test.
To compare different related variables, non-parametric
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Friedman tests for repeated measures were performed with
Wilcoxon post hoc test (non-normal distribution).
RESULTS
Relevant demographic and clinical data of the patient population
at baseline are summarised in Table 1. There were no patient
dropouts during the experimental period, all flow settings were
maintained according to the protocol and no adverse events
were recorded. Table 2 shows the dialysis durations and the ul-
trafiltration rates in the six test sessions. Since none of the test
sessions had to be terminated prematurely due to fibre clotting
in the dialyser, all patients completed each of the six arms of the
study protocol. One session was terminated early at 210 min due
to a machine problem, but without any sign of fibre clotting as
could be concluded from the dialyser scan post-dialysis.
The reconstructed images of the cross-sections halfway the
outlet potting are presented in Figure 1 for the 10 patients and
the six experimental dialysis sessions. The lumens of open
fibres are visualised as black dots.
The number of open fibres in the three non-used Solacea
TM
dia-
lyser reference samples was very consistent, being 12 087 6 4.
The relative number of open fibres in the six tested dialysis
scenarios for the thresholds of 50, 70 and 90% open fibre area
are presented in Table 3. For the threshold of fibres being open
for 70%, the median relative number of open fibres was 0.96
(pre-HDF), 0.99 (HD) and 0.97 (post-HDF) with one-quarter anti-
coagulation, while this was 0.76 (pre-HDF), 0.80 (HD) and 0.94
(post-HDF) with zero anticoagulation. Testing for repeated
measures showed a significant difference within the six strate-
gies (Friedman P< 0.001). Only for pre-HDF and HD, the relative
number of patent fibres was lower with zero anticoagulation as
compared with one-quarter anticoagulation, irrespective of the
considered threshold for counting open fibres (P¼ 0.004, respec-
tively, 0.013 for 70% threshold). No difference was seen in post-
HDF between zero and one-quarter anticoagulation. The antico-
agulation dose (P< 0.001) but not the dialysis mode (P¼ 0.116)
influenced the number of open fibres (threshold 70% open area).
Figure 2 shows the relative number of fibres considered as
open according to the three different thresholds (%) of individ-
ual fibre area free of clotting. Only a small drop (7–11%) can be
seen when the fibre counting criterion shifts from 70 to 90%
open fibre area, indicating that the fibres of Solacea
TM
are resis-
tant to even small degrees of fibre blocking during dialysis.
DISCUSSION
This cross-over study investigated the performance of the
Solacea
TM
dialyser with respect to fibre blocking in three differ-
ent dialysis modes, i.e. pre-HDF, HD and post-HDF, and using
either one-quarter or zero anticoagulation. Our main findings
are that first, Solacea
TM
performs excellently in avoiding clotting
as expressed by the relative number of open fibres at the end of
the dialysis session with only one-quarter of anticoagulation;
secondly, with zero anticoagulation, fibre blocking was more
prominent but still rather limited and no sessions had to be ter-
minated prematurely; and thirdly, the dialysis mode (pre-HDF
versus HD versus post-HDF) did not influence the number of
open fibres.
To avoid premature termination of the dialysis session and
the potential loss of patient’s blood due to clotting in the ECC,
many dialysis centres have the strategy to administer generous
amounts of anticoagulants. However, in conditions of active
bleeding or a substantial bleeding risk, systemic anticoagulation
might be contraindicated and strategies applying regional anti-
coagulation or even no anticoagulation should be used.
In the latter case, it is important to use biocompatible ECCs
and dialysers since activation of the coagulation cascade is
influenced by bio-incompatibility [8]. When using the Solacea
TM
dialyser without anticoagulation, we observed a substantial
reduction in percentage of open fibres in only 3/10 patients,
while all sessions could be completed as planned, i.e. after
240 min. Hence, our present findings confirm the advantageous





which makes this dialyser to be recommended for use in
settings when no systemic anticoagulation can be used.
This strategy seems even preferable above local anticoagula-
tion using citrate or calcium zero dialysate since these techni-
ques are quite labour intensive [9], and small single-centre
studies showed varying success [10, 11]. Also, the use of
Table 1. Demographic and clinical data of the patient population at
baseline
Gender (male/female) 9/1
Age, years, mean 6 SD 58.6 6 17.0




Renal disease IgA nephropathy (n¼2); renal cell
carcinoma (n¼ 2); diabetic ne-
phropathy (n¼ 1); nephroangio-
sclerosis (n¼ 1); focal
segmental glomerulosclerosis
(n¼ 1); retroperitoneal fibrosis
(n¼ 1); pauci-
immune crescentic glomerulo-
nephritis (n¼ 1); Alport (n¼ 1)
Regular anticoagulation
dose
Tinzaparin 4500 (n¼ 5); tinzaparin
3500 (n¼ 5)
Plt inhibitors Acetylsalicylic acid 80 mg (n¼ 5)
Hb, g/dL, mean 6 SD 11.3 6 0.5
Plts count, 103/mL, mean 6 SD 242 6 124
aPTT (s), mean 6 SD 40.0 6 7.4
INR (), mean 6 SD 1.0 6 0.1
CRP, mg/L, median (25pct–75pct) 4.1 (3.0–4.5)
IgA, immunoglobulin A; Hb, haemoglobin; aPTT, activated partial thromboplas-
tin time; INR, international normalised ratio; CRP, C-reactive protein.
Table 2. Characteristics of the dialysis sessions in the different ex-
perimental settings
Dialysis mode Dialysis duration (min) VUF (mL)
Pre-HDF_1/4 237 6 10a 2264 6 561
HD_1/4 240 6 1 2389 6 623
Post-HDF_1/4 239 6 4 2254 6 775
Pre-HDF_0 241 6 2 2385 6 670
HD_0 240 6 0 2496 6 628
Post-HDF_0 242 6 3 2341 6 665
Values are presented as mean 6 SD.
VUF, ultrafiltration volume over the session; pre-HDF_1/4, pre-HDF with one-
quarter anticoagulation; HD_1/4, HD with one-quarter anticoagulation; post-
HDF_1/4, post-HDF with one-quarter anticoagulation; pre-HDF_0, pre-HDF with
zero anticoagulation; HD_0, HD with zero anticoagulation; post-HDF_0, post-
HDF with zero anticoagulation.
aOne session was terminated at 210 min due to a machine problem without co-
agulation problems.
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dialysers with a heparin-coated membrane can be questionable,
although their use is meanwhile established in clinical practice
based on the results of observational and uncontrolled studies
[12, 13]. Controlled studies, however, reported medium to high
failure rates [2, 14]. In line with these reports, a more recent
cross-over study also failed to support the use of dialysers with
heparin-coated membranes in the setting of 4-h heparin-free
HD [15].
Periodic saline flushes can be performed when anticoagula-
tion is contraindicated. However, this is a laborious technique,
which also can result in fluid overload in the patient [16, 17]. As
an alternative, pre-HDF was then suggested and increasingly
FIGURE 1: Cross-sections halfway the potting in 10 patients and six tested settings. The greyscale range is from 0 to 0.5 cm1 and the scale bar denotes 10 mm.








niversity user on 23 April 2021
used [1, 2]. This strategy allows continuous rinsing of the circuit
without the risk of fluid overload. We summarize the literature
on this topic in Table 4. While a non-randomized study showed
promising results for pre-HDF versus standard HD [21], different
studies, however, found more clotting with saline flushes [4], as
well as with pre-HDF compared with standard HD [3, 27]. For pre-
HDF as compared with HD with a heparin-coated membrane,
Laville et al. found more clotting with pre-HDF [2], while Brunot
et al. found comparable results, ascribing the observed clotting to
preceding surgery or lower blood flows (<250 mL/min) [24].
The theoretical rationale to perform pre-HDF to avoid
clotting is the belief that the infusion is rinsing the membrane
continuously, avoiding adhesion of cells and proteins involved
in blood coagulation [29]. Besides the already described hyper-
coagulability of haemodilution as with saline flushes [30, 31],
the enhanced convective flux through the membrane with pre-
HDF might also promote coagulation by the increased protein
and cell adhesion on the membrane. Furthermore, pre-dilution
also increases blood flow in the fibre and, with it, wall shear
stress [27, 32]. Higher shear implies more diffusion from Plts to-
wards the membrane, where they preferentially bind to von
Willebrand factor (vWF) when the wall shear rate exceeds 630/s
[33]. Further increasing shear rate can even make the vWF
change from a lobular shape into a string, increasing tremen-
dously the number of Plt binding sites [32]. In the Solacea
TM
dialyser, containing 12 087 fibres of 200 mm diameter, the thresh-
old of 630/s wall shear rate is already surpassed at a blood flow
of 360 mL/min onwards in HD mode; when the number of fibres
is, however, decreased due to clotting to a number <10 105, this
already happens at a blood flow rate of 300 mL/min in standard
HD. As shear stress is further enhanced during haemofiltration,
it can be postulated that current dialyser designs and dialysis
protocols favour activation of coagulation by this pathway, and
even more in pre-HDF, where filtration rates are highest. This
mechanism might also explain why coagulation during dialysis
is a non-linear phenomenon, but rather follows an exponential
pattern.
To avoid haemodilution and high shear rates, also post-HDF
has been investigated as a potential alternative, but several
studies concluded that this strategy also resulted in more clot-
ting problems than standard HD [19, 20, 23, 26] (Table 4). In this
study, however, only anticoagulation dose but not HDF versus
HD influenced the number of clotted fibres.
The small patient number (n¼ 10) could be considered a lim-
itation of the study, but this allowed us to have each patient as
his/her own control over the six experimental regimens.
Furthermore, a post hoc power calculation revealed a power of
0.877 (one-way analysis of variance (ANOVA), Power and
Sample Size, SAS Inc., Cary, NC, USA).
Our study has several strengths. First, we were using the
same type of dialyser in all three dialysis strategies, and the
same amount of coagulant (either one-quarter of the normal
dose or zero), administered always in an identical manner (i.e.
single bolus at the dialysis start). This allowed us to make a di-
rect comparison among dilution strategies. It is likely that other
studies show seemingly contradictory results as they used dif-
ferent combinations of dialysers, anticoagulation strategies and
degrees of dilution in different arms, making direct analysis of
the singled out effect of dilution cumbersome (Table 4).
Secondly, while all studies summarised in Table 4 were making
conclusions about coagulation based on simple visual inspec-
tion, premature termination of the session and/or unspecific
coagulation parameters, we used a very sensitive technique to
Table 3. Percentage of open fibres in the SolaceaTM dialyser in the
six tested dialysis scenarios for the thresholds of 50, 70 and 90%
open fibre area
% 50% open area 70% open area 90% open area
Friedman P-value <0.001 <0.001 <0.001
Pre-HDF_1/4 96 (87–99) 96 (87–99) 91 (81–92)
HD_1/4 99 (97–99) 99 (97–99) 87 (86–91)
Post-HDF_1/4 97 (92–100) 97 (92–99) 88 (81–91)
Pre-HDF_0 76 (61–85)* 76 (61–85)* 69 (56–79)*
HD_0 81 (77–90)* 80 (77–89)* 72 (64–79)*
Post-HDF_0 94 (82–98) 94 (82–97) 86 (73–88)
Pre-HDF_1/4, pre-HDF with one-quarter anticoagulation; HD_1/4, HD with one-
quarter anticoagulation; post-HDF_1/4, post-HDF with one-quarter anticoagula-
tion; pre-HDF_0, pre-HDF with zero anticoagulation; HD_0, HD with zero antico-
agulation; post-HDF_0, post-HDF with zero anticoagulation.
Data are presented as median (25pct–75pct).
*P<0.05 versus one-quarter anticoagulation.
FIGURE 2: Relative number of fibres considered as open according to different decision criteria of % of fibre area free of clotting. Pre-HDF 1/4, pre-HDF with one-quarter
anticoagulation; HD 1/4, HD with one-quarter anticoagulation; post-HDF 1/4, post-HDF with one-quarter anticoagulation; pre-HDF 0, pre-HDF with zero anticoagula-
tion; HD 0, HD with zero anticoagulation; post-HDF 0, post-HDF with zero anticoagulation.
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measure coagulation based on the objective counting of the
number of blocked fibres [7].
In conclusion, the Solacea
TM
membrane performs very well
even in conditions where systemic anticoagulation is prohibited
and thus no single anticoagulant can be applied. We did not
find evidence to support that pre-dilution has a beneficial im-
pact on coagulation in such a setting.
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